EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PIPAC for Gastrointestinal Malignancies

Sara K Daniel, Beatrice J Sun, Byrne Lee

Journal of Clinical Medicine · 27.10.2023 · 12 (21) · 6799

DOI: 10.3390/jcm12216799 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.10.2023. Verfasst von Sara K Daniel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Stanford University, Stanford, CA 94305, USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The peritoneum is a common site of metastases for gastrointestinal tumors that predicts a poor outcome. In addition to decreased survival, peritoneal metastases (PMs) can significantly impact quality of life from the resulting ascites and bowel obstructions. The peritoneum has been a target for regional therapies due to the unique properties of the blood–peritoneum barrier. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) have become accepted treatments for limited-volume peritoneal disease in appendiceal, ovarian, and colorectal malignancies, but there are limitations. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) improves drug distribution and tissue penetration, allowing for a minimally invasive application for patients who are not CRS/HIPEC candidates based on high disease burden. PIPAC is an emerging treatment that may convert the patient to resectable disease, and may increase survival without major morbidity, as indicated by many small studies. In this review, we discuss the rationale and benefits of PIPAC, as well as sentinel papers describing its application for gastric, colorectal, appendiceal, and pancreatobiliary PMs. While no PIPAC device has yet met FDA approval, we discuss next steps needed to incorporate PIPAC into neoadjuvant/adjuvant treatment paradigms, as well as palliative settings. Data on active clinical trials using PIPAC are provided.

Schlagwörter

Stichwörter der Autor:innen

PIPACintraperitoneal chemotherapyperitoneal metastases

Autor:innen und Institutionen

  • Department of Surgery, Stanford University, Stanford, CA 94305, USA.

Zitieren

APA

Daniel, S. K., Sun, B. J., & Lee, B. (2023). PIPAC for Gastrointestinal Malignancies. Journal of Clinical Medicine, 12(21), 6799. https://doi.org/10.3390/jcm12216799

Vancouver

Daniel SK, Sun BJ, Lee B. PIPAC for Gastrointestinal Malignancies. Journal of Clinical Medicine. 2023;12(21):6799. doi:10.3390/jcm12216799

BibTeX
@article{Daniel2023,
  author = {Daniel, Sara K and Sun, Beatrice J and Lee, Byrne},
  title = {PIPAC for Gastrointestinal Malignancies},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {21},
  pages = {6799},
  doi = {10.3390/jcm12216799}
}
Kostenlos starten →